$Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center$
Código QR

Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center

Objective To compare the efficacy and prognosis of imatinib and sirolimus as second-line treatment for steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 33 patients diagnosed as SR-cGVHD afte...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	HE Yundi, HUANG Ruihao, HONG Tao, WANG Weihao, DU Yuxuan
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Office of Journal of Third Military Medical University 2021
Materias:	chronic graft-versus-host disease allogeneic hematopoietic stem cell transplantation imatinib sirolimus Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/413c7351afd84e67a2f6d92b036de682
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:413c7351afd84e67a2f6d92b036de682
record_format	dspace
spelling	oai:doaj.org-article:413c7351afd84e67a2f6d92b036de6822021-11-12T04:44:39ZSirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center10.16016/j.1000-5404.2021080671000-5404https://doaj.org/article/413c7351afd84e67a2f6d92b036de6822021-11-01T00:00:00Zhttp://aammt.tmmu.edu.cn/Upload/rhtml/202108067.htmhttps://doaj.org/toc/1000-5404Objective To compare the efficacy and prognosis of imatinib and sirolimus as second-line treatment for steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 33 patients diagnosed as SR-cGVHD after allo-HSCT in the Medical Center of Hematology of Army Medical University from September 2017 to December 2020 were collected and analyzed retrospectively. Among them, 16 patients were treated with imatinib and 17 with sirolimus. The response rate at the time points of 6 months and 1 year after initiation of second-line treatment, 2-year overall survival (OS), 2-year disease free survival (DFS), 1-year failure free survival and drug-related toxicity were compared between the 2 groups. Results For the imatinib and sirolimus patients, their 6-month overall response rate (ORR) was 62.5% and 41.2% (P=0.303), while 1-year ORR was 73.3% and 43.8% (P=0.149), 6-month complete response (CR) rate was 12.5% and 23.5% (P=0.656), while 1-year CR rate was 20.0% and 31.3% (P=0.685), respectively, and no statistical significance was observed between the 2 groups. The patients with imatinib treatment achieved better outcomes than those treated with sirolimus in terms of 2-year OS and 2-year DFS (P=0.041, P=0.043). There was no significant difference in the occurrence of drug-related toxicity between the 2 groups. Conclusion Imatinib and sirolimus shows similar response rate to SR-cGVHD after allo-HSCT, but the former is superior to the latter in terms of short-term OS and DFS.HE YundiHUANG RuihaoHONG TaoWANG WeihaoDU YuxuanEditorial Office of Journal of Third Military Medical Universityarticlechronic graft-versus-host diseaseallogeneic hematopoietic stem cell transplantationimatinibsirolimusMedicine (General)R5-920ZHDi-san junyi daxue xuebao, Vol 43, Iss 21, Pp 2313-2320 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	chronic graft-versus-host disease allogeneic hematopoietic stem cell transplantation imatinib sirolimus Medicine (General) R5-920
spellingShingle	chronic graft-versus-host disease allogeneic hematopoietic stem cell transplantation imatinib sirolimus Medicine (General) R5-920 HE Yundi HUANG Ruihao HONG Tao WANG Weihao DU Yuxuan Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
description	Objective To compare the efficacy and prognosis of imatinib and sirolimus as second-line treatment for steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 33 patients diagnosed as SR-cGVHD after allo-HSCT in the Medical Center of Hematology of Army Medical University from September 2017 to December 2020 were collected and analyzed retrospectively. Among them, 16 patients were treated with imatinib and 17 with sirolimus. The response rate at the time points of 6 months and 1 year after initiation of second-line treatment, 2-year overall survival (OS), 2-year disease free survival (DFS), 1-year failure free survival and drug-related toxicity were compared between the 2 groups. Results For the imatinib and sirolimus patients, their 6-month overall response rate (ORR) was 62.5% and 41.2% (P=0.303), while 1-year ORR was 73.3% and 43.8% (P=0.149), 6-month complete response (CR) rate was 12.5% and 23.5% (P=0.656), while 1-year CR rate was 20.0% and 31.3% (P=0.685), respectively, and no statistical significance was observed between the 2 groups. The patients with imatinib treatment achieved better outcomes than those treated with sirolimus in terms of 2-year OS and 2-year DFS (P=0.041, P=0.043). There was no significant difference in the occurrence of drug-related toxicity between the 2 groups. Conclusion Imatinib and sirolimus shows similar response rate to SR-cGVHD after allo-HSCT, but the former is superior to the latter in terms of short-term OS and DFS.
format	article
author	HE Yundi HUANG Ruihao HONG Tao WANG Weihao DU Yuxuan
author_facet	HE Yundi HUANG Ruihao HONG Tao WANG Weihao DU Yuxuan
author_sort	HE Yundi
title	Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
title_short	Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
title_full	Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
title_fullStr	Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
title_full_unstemmed	Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
title_sort	sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
publisher	Editorial Office of Journal of Third Military Medical University
publishDate	2021
url	https://doaj.org/article/413c7351afd84e67a2f6d92b036de682
work_keys_str_mv	AT heyundi sirolimusversusimatinibinpatientswithsteroidrefractorychronicgraftversushostdiseasearetrospectiveanalysisofasinglecenter AT huangruihao sirolimusversusimatinibinpatientswithsteroidrefractorychronicgraftversushostdiseasearetrospectiveanalysisofasinglecenter AT hongtao sirolimusversusimatinibinpatientswithsteroidrefractorychronicgraftversushostdiseasearetrospectiveanalysisofasinglecenter AT wangweihao sirolimusversusimatinibinpatientswithsteroidrefractorychronicgraftversushostdiseasearetrospectiveanalysisofasinglecenter AT duyuxuan sirolimusversusimatinibinpatientswithsteroidrefractorychronicgraftversushostdiseasearetrospectiveanalysisofasinglecenter
_version_	1718431226433372160

Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center

Ejemplares similares